Mario Blanco-Blanco
@imibic.org
GE07 Visual Quality / Maimonides Biomedical Research Institute of Cordoba (IMIBIC)
Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Department of Ophthalmology, Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
EDUCATION
Optics and Optometry Bachelor Degree, University of Granada, Granada, Spain, 2018
Clinical Optometry and Advanced Optics Master Degree, University of Granada, Granada, Spain, 2020
RESEARCH, TEACHING, or OTHER INTERESTS
Optometry, Mechanics of Materials, Biomaterials, Ophthalmology
Scopus Publications
Scopus Publications
Raúl Martínez-Castillo, Carmen González-Gallardo, José I. Muñoz-Ávila, Pilar Font, Marta Villalba-González, Indira Stoikow, Ignacio Fernández-Choquet de Isla, Francisco Pugliese, Roberto Anaya-Alaminos, José L. García-Serrano,et al.
Elsevier BV
Yolanda Jiménez-Gómez, David Alba-Molina, Mario Blanco-Blanco, Lorena Pérez-Fajardo, Felisa Reyes-Ortega, Laura Ortega-Llamas, Marta Villalba-González, Ignacio Fernández-Choquet de Isla, Francisco Pugliese, Indira Stoikow,et al.
MDPI AG
In recent years, the number of patients with ocular diseases is increasing as a consequence of population aging. Among them, one of the most common is the age-related macular degeneration (AMD), a condition that leads to vision loss if it is not treated. AMD is a multifactorial disorder with two advanced forms, dry and neovascular AMD. Currently, although there is no approved therapy that significantly impacts dry AMD progression, several pharmacologic therapies exist for neovascular AMD. Notwithstanding, evidence suggests a suboptimal result in a high number of patients receiving these therapeutic options. Consequently, finding effective strategies is not only a still unmet medical need in dry AMD but also in neovascular AMD. This underlines the need for new drug delivery technologies that can improve the pharmacological action and drug concentration at the target sites. In this regard, sustained drug delivery systems are presented as the most promising therapeutic options in AMD patients. This review summarized the pathogenesis and the current treatment options for AMD, focusing on the emerging ocular sustained drug delivery approaches undergoing clinical trials.
RECENT SCHOLAR PUBLICATIONS
Publications
Martínez-Castillo, R.; González-Gallardo, C.; Muñoz-Ávila, J.I.; Font, P.; Villalba-González, M.; Stoikow, I.; Fernández-Choquet de Isla, I.; Pugliese, F.; Anaya-Alaminos, R.; García-Serrano, J.L.; Hermoso-Fernández, F.; Contieri, F.; Muñoz-de-Escalona-Rojas, J.E.; Pérez-Fajardo, L.; Blanco-Blanco, M.; Jiménez-Gómez, Y.; González-Andrades, M. Treatment of neovascular age-related macular degeneration within 48 h from diagnosis improves long-term functional outcome. Biomedicine & Pharmacotherapy, 2023, 160.
Jiménez-Gómez, Y.; Alba-Molina, D.; Blanco-Blanco, M.; Pérez-Fajardo, L.; Reyes-Ortega, F.; Ortega-Llamas, L.; Villalba-González, M.; Fernández-Choquet de Isla, I.; Pugliese, F.; Stoikow, I.; González-Andrades, M. Novel Treatments for Age-Related Macular Degeneration: A Review of Clinical Advances in Sustained Drug Delivery Systems. Pharmaceutics 2022, 14, 1473.